ResourcesLearn from our biopharma experts, explore stimulating thought leadership and see some of our clients’ past successes.
The Prescient team has prepared a white paper discussing our view on the recent advances in the CAR-T landscape. Industry and academia appear to be making significant strides in simplifying manufacturing and administration processes, expanding clinical utility and enabling access for patients. By: Ben Doran, Stuart Crichton, Ben Druck and Vasiliki Patsioura Click below and complete the form to receive the white paper via email.Read More
Our client, a global pharmaceutical company, was planning to launch a second-in-class biologic in a crowded market space. However, the market was facing a potential game changer with the launch of an oral option that posed a threat to all biologic therapies. The client partnered with Prescient to maximize its market potential and optimize its positioning and messaging, both against same-class competitors and the soon-to-launch oral competitor.
Our global pharmaceutical client needed insights into the then-unknown biosimilars space and assistance in successfully defending its franchises. It engaged Prescient to undertake a worldwide project that would: 1) develop and maintain a landscape of biosimilars; 2) monitor the clinical and regulatory timelines of key biosimilar competitors; 3) identify the commercial launch strategies of competitors and their implications for the client; and 4) monitor changes in different countri[...]
Our global pharmaceutical client’s drug had one of the most successful launches in its category and monopolized the market for years. Another company, however, launched a product that was in direct competition, resulting in decreasing sales driven by losses in new prescriptions and aggressive commercialization of the new drug. Our client had recently launched certain initiatives to respond to the loss in revenues. The client engaged Prescient to anticipate and counter the competit[...]
Due to the increase in incidence of a particular disease worldwide, our client, a global pharmaceutical company, wanted to strengthen its future product portfolio to meet the needs of patients affected by this disease. The company partnered with Prescient to undertake a robust patient segmentation exercise to predict the level of need and the anticipated uptake within each segment of both marketed and pipeline products. The client also had a specific product in mind, so it was looki[...]
Our client, a global pharmaceutical company, was planning to launch an immunology agent. Although competitor products in the therapy area were more efficacious, the client’s new agent had a more convenient route of administration, and clinical trials demonstrated it to be safer. Recognizing the need to create a brand that is positively differentiated from the competition, our client engaged Prescient to develop a positioning and messaging strategy that would communicate the safety[...]
Our client, a global pharmaceutical company, had a biologic in development for the treatment of a condition with a large uncontrolled population. It partnered with Prescient to both understand the target patient pool where product uptake would be the highest, and to optimize the target product profile (TPP) for commercial success.
Years of non-small cell lung cancer (NSCLC) research are beginning to result in significant gains in the standard of care, specifically for patients eligible for anti-PD-1 therapy. As all anti-PD-1s have the same pricing, the benefit of multiple approvals has not resulted in typical market behavior. The future challenge is to define the immunotherapy landscape and combination rationale, with a personalized, patient-centric approach.